Aller au contenu principal
Profil bibliographique

Chiara Maria Catena Sorbello

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

5Publications signalées
1Citations signalées
3Affiliations récentes

Les institutions déclarées

Les domaines associés

Platelet Disorders and TreatmentsMultiple Myeloma Research and TreatmentsComplement system in diseasesCoagulation, Bradykinin, Polyphosphates, and AngioedemaBlood Coagulation and Thrombosis Mechanisms

Les publications récentes

Accès ouvert 2026 article OpenAlex

The impact of caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura. A retrospective monocentric cohort study

Uroš Markovic, Gabriele Sapuppo, Sara Frazzetto, Stephanie Grasso et autres

Background: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder caused by severe ADAMTS13 deficiency, leading to microvascular platelet-rich thrombi, hemolysis, and organ damage, mainly involving brain, heart, kidneys, and intestines. Standard treatment includes plasma exchange (PEX) and immunosuppressants. Caplacizumab (CAPLA), …

it, ru (code pays fourni par la source)

0 citations Frontiers in Pharmacology
Accès ouvert 2026 article OpenAlex

Long-Term Survival with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients—A Survey from Two Italian Centers

Vittorio Del Fabro, Lara Gullo, Giuliana Giunta, Giuseppina Uccello et autres

BACKGROUND: Multiple myeloma (MM) is a clonal plasma cell neoplasm representing the second most common hematological malignancy. The combination of daratumumab, lenalidomide and dexamethasone (D-Rd) was first approved by the EMA (European Medicines Agency) for the treatment of relapsed/refractory multiple myeloma (RRMM) …

it (code pays fourni par la source)

0 citations Diseases
Accès ouvert 2025 article OpenAlex

Inhibitor Eradication in Postpartum Acquired Haemophilia A: Real‐Life Case Series and Literature Review

Gaetano Giuffrida, Uroš Markovic, Stephanie Grasso, Andrea Duminuco et autres

BACKGROUND: Acquired haemophilia A (AHA) is a rare and severe bleeding disorder generally associated with pregnancy or aging. Spontaneous remission and prompt inhibitor eradication are described more frequently in postpartum cases. We evaluated retrospectively 15 postpartum AHA cases between 2007 and 2023 …

it (code pays fourni par la source)

0 citations Haemophilia
2024 conference-abstract OpenAlex

Effectiveness of Adjunctive Caplacizumab Treatment in Immune Thrombotic Thrombocytopenic Purpura in Real-Life Setting. Retrospective Monocentric Cohort

Uroš Markovic, Sara Frazzetto, Stephanie Grasso, Giuliana Giunta et autres

Introduction. Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disease caused by a severe deficiency of the metalloproteinase ADAMTS13, that results in platelet-rich thrombi in the microvessels, with subsequent red cells fragmentation and end-organ damage, predominantly affecting the brain, heart, kidneys …

it (code pays fourni par la source)

0 citations Blood
Accès ouvert 2024 article OpenAlex

IgG-k/IgG-λ Para-Osseous Plasmacytoma Relapsed as Soft-Tissue Plasmacytoma with IgA-k Immunophenotype: A Case Report and Review of the Literature on Related Biochemical Aspects

Manlio Fazio, Chiara Maria Catena Sorbello, Vittorio Del Fabro, Alessandra Romano et autres

Neoplastic plasma cells (PCs) proliferation at anatomic sites dislocated from the bone marrow (BM) or their contiguous growth from osseous lesions that disrupt the cortical bone is termed extramedullary multiple myeloma (EMD). EMD still remains challenging from a therapeutic and biological perspective. …

it (code pays fourni par la source)

1 citation Hematology Reports

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.